HomeAboutMediaCareersSite MapContactSearch
Geron
PatientsProductsTechnology & ScienceInvestors
print
Recent Publications
  • Nature Reviews Cancer
    8:167-179, March 2008
  • Nature Biotechnology
    25:1015-1024, Sept. 2007
News
  • 8/12/2008
    Geron and Exeter Life Sciences Merge Start Licensing and Viagen To Form Combined Licensing and Operating Company for Animal Cloning Technologies ...more 
  • 8/7/2008
    Geron Initiates Clinical Trial of GRN163L in Combination with Paclitaxel and Bevacizumab in Patients with Breast Cancer ...more 
Events
  • July 31, 2008, 8:00am PT
    Q2 2008 Conference Call, Menlo Park, CA
    Click here for access to webcast.
  • September 3-5, 2008
    Thomas Weisel Healthcare Conference, Boston, MA

Uncommon Medicine / Unlimited Potential

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. We are advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. We are also the world leader in the development of human embryonic stem cell-based therapeutics, with our spinal cord injury treatment anticipated to be the first product to enter clinical development.

Visionary Therapeutics
Home | About | Media | Careers | Site Map | Contact | Search
Patients | Products | Technology & Science | Investors
Legal Disclaimer
Copyright © Geron 2008. All rights reserved.
Site design and layout by BFW Interactive